ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe

Particle and Fibre Toxicology

Joppe WR Hovius²  Theo P Schetters⁷  Boris Klempa⁸  Sabina Havlíková⁸  Bjorn Rotter³  Peter Winter³  Juan Anguita¹  Ard M Nijhof⁴  Radek Šíma⁵  Petr Kopáček⁵  Ondřej Hajdušek⁵  Ryan OM Rego⁵  Libor Grubhoffer⁵  Ingar Seemann²  Jos Trentelman²  Hein Sprong⁶ 

[1] Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain and Ikerbasque Foundation, Bilbao, Spain;Academic Medical Center, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam, The Netherlands;GenXPro GmbH (GenXPro), Frankfurt am Main, Germany;Institute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin (FUB), Berlin, Germany;Biology Centre of the Academy of Sciences of the Czech Republic (BC ASCR), České Budějovice, Czech Republic;The National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands;Merck Sharp & Dohme Animal Health, Boxmeer, The Netherlands;Institute of Virology, Slovak Academy of Sciences (IV SAS), Bratislava, Slovak Republic

关键词: Public health;    Babesiosis;    Tick-borne encephalitis;    Lyme borreliosis;    Vaccine;    Ixodes ricinus;   

Others  :  812073
DOI  :  10.1186/1756-3305-7-77

 received in 2014-02-07, accepted in 2014-02-19,  发布年份 2014

【 摘 要 】

Ixodes ricinus transmits bacterial, protozoal and viral pathogens, causing disease and forming an increasing health concern in Europe. ANTIDotE is an European Commission funded consortium of seven institutes, which aims to identify and characterize tick proteins involved in feeding and pathogen transmission. The knowledge gained will be used to develop and evaluate anti-tick vaccines that may prevent multiple human tick-borne diseases. Strategies encompassing anti-tick vaccines to prevent transmission of pathogens to humans, animals or wildlife will be developed with relevant stakeholders with the ultimate aim of reducing the incidence of tick-borne diseases in humans.

【 授权许可】

   
2014 Sprong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rizzoli A, Hauffe H, Carpi G, Vourc HG, Neteler M, Rosa R: Lyme borreliosis in Europe. Euro Surveill 2011., 16(27) Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19906 webcite
• [2]Jaenson TG, Hjertqvist M, Bergstrom T, Lundkvist A: Why is tick-borne encephalitis increasing? A review of the key factors causing the increasing incidence of human TBE in Sweden. Parasite Vectors 2012, 5:184. BioMed Central Full Text
• [3]Haglund M, Gunther G: Tick-borne encephalitis–pathogenesis, clinical course and long-term follow-up. Vaccine 2003, 21(Suppl 1):S11-S18.
• [4]Heyman P, Cochez C, Hofhuis A, van der Giessen J, Sprong H, Porter SR, Losson B, Saegerman C, Donoso-Mantke O, Niedrig M, Papa A: A clear and present danger: tick-borne diseases in Europe. Expert Rev Anti Infect Ther 2010, 8:33-50.
• [5]Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, Oei A, Knol H, Narasimhan S, Hodiamont CJ, Jahfari S, Pals ST, Horlings HM, Fikrig E, Sprong H, van Oers MH: A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet 2013, 382:658.
• [6]Martinot M, Zadeh MM, De Briel D: Human babesiosis. N Engl J Med 2012, 367:1070. author reply 1071–1072
• [7]Sumilo D, Bormane A, Vasilenko V, Golovljova I, Asokliene L, Zygutiene M, Randolph S: Upsurge of tick-borne encephalitis in the Baltic States at the time of political transition, independent of changes in public health practices. Clin Microbiol Infect 2009, 15:75-80.
• [8]Jahfari S, Fonville M, Hengeveld P, Reusken C, Scholte EJ, Takken W, Heyman P, Medlock J, Heylen D, Kleve J, Sprong H: Prevalence of Neoehrlichia mikurensis in ticks and rodents from North-west Europe. Parasite Vectors 2012, 5:74. BioMed Central Full Text
• [9]Medlock JM, Hansford KM, Bormane A, Derdakova M, Estrada-Pena A, George JC, Golovljova I, Jaenson TG, Jensen JK, Jensen PM, Kazimirova M, Oteo JA, Papa A, Pfister K, Plantard O, Randolph SE, Rizzoli A, Santos-Silva MM, Sprong H, Vial L, Hendrickx G, Zeller H, Van Bortel W: Driving forces for changes in geographical distribution of Ixodes ricinus ticks in Europe. Parasite Vectors 2013, 6:1. BioMed Central Full Text
• [10]Sprong H, Hofhuis A, Gassner F, Takken W, Jacobs F, van Vliet AJ, van Ballegooijen M, van der Giessen J, Takumi K: Circumstantial evidence for an increase in the total number and activity of Borrelia-infected Ixodes ricinus in the Netherlands. Parasite Vectors 2012, 5:294. BioMed Central Full Text
• [11]Stefanoff P, Rosinska M, Samuels S, White DJ, Morse DL, Randolph SE: A national case–control study identifies human socio-economic status and activities as risk factors for tick-borne encephalitis in Poland. PLoS One 2012, 7:e45511.
• [12]Godfrey ER, Randolph SE: Economic downturn results in tick-borne disease upsurge. Parasite Vectors 2011, 4:35. BioMed Central Full Text
• [13]Kunze U, TBE I: Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE). Vaccine 2011, 29:1355-1356.
• [14]Lindgren E, Andersson Y, Suk JE, Sudre B, Semenza JC: Public health. Monitoring EU emerging infectious disease risk due to climate change. Science 2012, 336:418-419.
• [15]Piesman J, Eisen L: Prevention of tick-borne diseases. Annu Rev Entomol 2008, 53:323-343.
• [16]Monath TP: Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine 2013, 31:5321-5338.
• [17]de la Fuente J, Almazan C, Canales M, de la Lastra JM P, Kocan KM, Willadsen P: A ten-year review of commercial vaccine performance for control of tick infestations on cattle. Anim Health Res Rev 2007, 8:23-28.
• [18]Torina A, Moreno-Cid JA, Blanda V, de Mera IG F, de la Lastra JM, Scimeca S, Blanda M, Scariano ME, Brigano S, Disclafani R, Piazza A, Vicente J, Gortazar C, Caracappa S, Lelli RC, de la Fuente J: Control of tick infestations and pathogen prevalence in cattle and sheep farms vaccinated with the recombinant Subolesin-major surface protein 1a chimeric antigen. Parasite Vectors 2014, 7:10. BioMed Central Full Text
• [19]Valle MR, Mendez L, Valdez M, Redondo M, Espinosa CM, Vargas M, Cruz RL, Barrios HP, Seoane G, Ramirez ES, Boue O, Vigil JL, Machado H, Nordelo CB, Pineiro MJ: Integrated control of Boophilus microplus ticks in Cuba based on vaccination with the anti-tick vaccine Gavac. Exp Appl Acarol 2004, 34:375-382.
• [20]Mulder S, van Vliet AJ, Bron WA, Gassner F, Takken W: High risk of tick bites in dutch gardens. Vector Borne Zoonotic Dis 2013, 13:865-871.
• [21]Rumyantsev AA, Goncalvez AP, Giel-Moloney M, Catalan J, Liu Y, Gao QS, Almond J, Kleanthous H, Pugachev KV: Single-dose vaccine against tick-borne encephalitis. Proc Natl Acad Sci U S A 2013, 110:13103-13108.
• [22]Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M: Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 2013, 19:69-76.
• [23]Wressnigg N, Pollabauer EM, Aichinger G, Portsmouth D, Low-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Bruhl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Muller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN: Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis 2013, 13:680-689.
• [24]Lantos PM: Lyme disease vaccination: are we ready to try again? Lancet Infect Dis 2013, 13:643-644.
• [25]Hajdusek O, Sima R, Ayllon N, Jalovecka M, Perner J, de la Fuente J, Kopacek P: Interaction of the tick immune system with transmitted pathogens. Front Cell Infect Microbiol 2013, 3:26.
• [26]Schuijt TJ, Narasimhan S, Daffre S, DePonte K, Hovius JW, Van't Veer C, van der Poll T, Bakhtiari K, Meijers JC, Boder ET, van Dam AP, Fikrig E: Identification and characterization of Ixodes scapularis antigens that elicit tick immunity using yeast surface display. PloS One 2011, 6:e15926.
• [27]Hovius JW, van Dam AP, Fikrig E: Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol 2007, 23:434-438.
• [28]de la Fuente J, Kocan KM, Blouin EF: Tick vaccines and the transmission of tick-borne pathogens. Vet Res Commun 2007, 31(Suppl 1):85-90.
• [29]Labuda M, Trimnell AR, Lickova M, Kazimirova M, Davies GM, Lissina O, Hails RS, Nuttall PA: An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog 2006, 2:e27.
• [30]Hovius JW, Levi M, Fikrig E: Salivating for knowledge: potential pharmacological agents in tick saliva. PLoS Med 2008, 5:e43.
• [31]Schuijt TJ, Coumou J, Narasimhan S, Dai J, Deponte K, Wouters D, Brouwer M, Oei A, Roelofs JJ, van Dam AP, van der Poll T, Van't Veer C, Hovius JW, Fikrig E: A tick mannose-binding lectin inhibitor interferes with the vertebrate complement cascade to enhance transmission of the lyme disease agent. Cell Host Microbe 2011, 10:136-146.
• [32]Dai J, Wang P, Adusumilli S, Booth CJ, Narasimhan S, Anguita J, Fikrig E: Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 2009, 6:482-492.
• [33]Ramamoorthi N, Narasimhan S, Pal U, Bao F, Yang XF, Fish D, Anguita J, Norgard MV, Kantor FS, Anderson JF, Koski RA, Fikrig E: The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 2005, 436:573-577.
• [34]Burke G, Wikel SK, Spielman A, Telford SR, McKay K, Krause PJ, Tick-borne Infection Study G: Hypersensitivity to ticks and Lyme disease risk. Emerg Infect Dis 2005, 11:36-41.
• [35]Braks M, van der Giessen J, Kretzschmar M, van Pelt W, Scholte EJ, Reusken C, Zeller H, van Bortel W, Sprong H: Towards an integrated approach in surveillance of vector-borne diseases in Europe. Parasite Vectors 2011, 4:192. BioMed Central Full Text